New imaging agent could light up Hard-to-See cancers

NCT ID NCT07117214

First seen Jun 25, 2026 · Last updated Jul 08, 2026 · Updated 3 times

Summary

This early-phase study tests a new radioactive imaging agent called [68Ga]Ga-DWJ155 in 36 adults with advanced breast cancer or non-small cell lung cancer. The agent is designed to bind to a target on cancer cells and show up on PET scans, helping doctors see where the cancer has spread. The main goals are to check how well the imaging works, how the agent spreads in the body, and whether it is safe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
[68Ga]Ga-DWJ155 (a radioactive imaging agent for PET scans)
What this could lead to
If successful, this could lead to a better way to detect and monitor advanced breast cancer and lung cancer using PET imaging, potentially guiding treatment decisions.
What could go wrong
This is a very early, first-in-human study with only 36 participants. The imaging agent may not clearly distinguish tumors from normal tissue, or safety issues could arise. It is not a treatment and will not directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Novartis Investigative Site

    RECRUITING

    Groningen, Provincie Groningen, 9728, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.